• Recruiting

NCT04614636: Phase 1 - FT538 in Subjects With Advanced Hematologic Malignancies

Updated: May 25

FT538

induced pluripotent stem cell-derived CD16/IL-15RF-expressing CD38-eliminated natural killer cells FT538


FT538


NCT04614636: Phase 1 - FT538 in Subjects With Advanced Hematologic Malignancies


This is a Phase I dose-finding study of FT538 as monotherapy in acute myeloid leukemia (AML) and in combination with monoclonal antibodies in multiple myeloma (MM). The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.


Sponsor

Fate Therapeutics

 

ClinicalTrials.gov Identifier: NCT04614636


Official Title: A Phase I, Open-Label, Multicenter Study of FT538 as Monotherapy in Relapsed/Refractory Acute Myelogenous Leukemia and in Combination With Monoclonal Antibodies in Relapsed/Refractory Multiple Myeloma


First Posted : November 4, 2020


Click here for details on ClinicalTrials.gov

 

FT 538

iPSC-derived CD16/IL-15RF-expressing CD38-eliminated NK Cells FT538 (Code C176623)

FT 538

FT-538

FT538

induced pluripotent stem cell-derived CD16/IL-15RF-expressing CD38-eliminated natural killer cells FT538

 

Drug: FT538

Drug: Cyclophosphamid

Drug: Fludarabine

Drug: Daratumumab

Drug: Elotuzumab

 

- Multiple locations

- New York: Memorial Sloan-Kettering Cancer Center New York

- Tennessee: Sarah Cannon Research Institute Nashville

- Missouri: Washington University School of Medicine Saint Louis

- Texas: The University of Texas MD Anderson Cancer Center Houston

 

Locations

United States, Colorado

United States, Minnesota

United States, Missouri

United States, New Jersey

United States, New York

United States, Tennessee

United States, Texas





Posts Archive